Physician profile
Maija Swanson
NPI 1659875714
$1,428.42
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $141 · 2023: $1,195 · 2024: $92.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,287.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $236.54 | 2023-2024 | Vraylar, Rinvoq, Qulipta |
| Lilly USA, LLC | $204.41 | 2022-2024 | Jardiance, Mounjaro, Emgality |
| Novo Nordisk INC | $145.00 | 2022-2023 | Wegovy, Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $142.36 | 2023-2024 | |
| Idorsia Pharmaceuticals US INC | $133.15 | 2023 | Quviviq |
| Amgen INC. | $91.37 | 2023 | Repatha, Otezla, Prolia |
| Glaxosmithkline, LLC. | $82.83 | 2022-2023 | Trelegy Ellipta, Arexvy |
| Biohaven Pharmaceutical Holding Company LTD. | $51.27 | 2022 | |
| Mylan Specialty L.P. | $50.60 | 2023 | Yupelri |
| Radius Health, INC. | $48.67 | 2023 | Tymlos |
| Biomerieux INC | $45.59 | 2023 | |
| Organon LLC | $42.86 | 2023 | Nexplanon, Jada System |
| Gilead Sciences, INC. | $40.12 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $27.28 | 2023 | Farxiga |
| Pfizer INC. | $20.78 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phadia US INC. | $18.74 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $16.38 | 2023 | |
| Dexcom, INC. | $15.56 | 2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.91 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maija Swanson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.